Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
ALN-2232: Dedicated RNAi program for obesity & weight management (Phase 1 data expected H2 2026) $4.9-$5.3B projected 2026 revenue, fueling aggressive expansion in metabolic and cardiometabolic pipelines 10+ tissue types & 40+ clinical programs targeted by 2030 ~30% of revenues reinvested into R&D, accelerating next-generation metabolic innovation Reinforces obesity's emergence as a foundational pillar of future medicine ------------------------------------------------------------- Stay up to date with everything obesity through my newsletter Todays popular weight-loss drugs (like Wegovy or Zepbound) are GLP-1 agonists
Real-World Applications in Connecticut Stamford patients report sustained energy for work/gym after 4 weeks
Ers A, Sos A, Hegyi P, et al
In mouse islets, the glucagonostatic effect of GLP-1(936) was also abolished by the GRA L-168049 [46] (ESM Fig
US$ 20.06
US$ 26.03
US$ 20.34
US$ 27.11
US$ 26.47
US$ 29.16
US$ 29.83
